[Thalidomide-associated hypothyroidism in a patient with multiple myeloma].

Abstract

Thalidomide is highly effective against multiple myeloma, but some patients must discontinue this medication due to adverse effects. We present herein an instructive case report on thalidomide-associated hypothyroidism in a patient with multiple myeloma. Thyroid hormone replacement therapy allowed us to restart administration of thalidomide, a potentially life-saving therapy. Known adverse effects of thalidomide, such as lethargy, constipation, and bradycardia, are potential symptoms of hypothyroidism, but we tend to overlook drug-associated hypothyroidism. Our case highlights the importance of routinely testing thyroid function in patients receiving thalidomide therapy.

• Authors: Ikue Okamura, Takashi Ikeda, Ken Sato, Fumihiko Kimura
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 56 Issue 1 Pg. 38-40 (Jan 2015) ISSN: 0485-1439 [Print] Japan
• PMID: 25745967 (Publication Type: Case Reports, Journal Article)

Chemical References

• Thalidomide
• Lenalidomide

Topics

• Aged
• Constipation (chemically induced)
• Humans
• Hypothyroidism (chemically induced, diagnosis)
• Lenalidomide
• Male
• Multiple Myeloma (drug therapy)
• Thalidomide (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Thyroid Function Tests (methods)